Literature DB >> 16924494

Functional CD8+ T cells infiltrate into nonsmall cell lung carcinoma.

Elizabeth M E Verdegaal1, Conny Hoogstraten, Maro H Sandel, Peter J K Kuppen, Antoinette A T P Brink, Frans H J Claas, Michael C B Gorsira, J Frans Graadt van Roggen, Susanne Osanto.   

Abstract

Infiltration of CD3(+)CD8(+) cytotoxic T cells was analyzed by multiparameter confocal laser microscopy in a panel of 16 randomly selected stage I nonsmall cell lung carcinomas. T-cell infiltration was observed in the stroma (range 57-2,093 T cells/mm(2)) but also in the tumor epithelium (range 21-892 T cells/mm(2)) and showed wide variation between individual tumors. Interestingly, a significantly higher percentage of CD3(+)CD8(+) T cells was detected in the tumor epithelium compared to the stroma illustrating that cytotoxic T cells may preferentially migrate into tumor epithelium. Aberrant HLA class I antigen expression was observed in 69% of the nonsmall-cell lung carcinoma (NSCLC) tumors. One tumor of a squamous cell lung carcinoma patient with the highest number of tumor infiltrating CD3(+) and CD3(+)CD8(+) cells was studied in detail and the majority (90%) of these cells were shown to be functionally activated granzyme B-positive cytotoxic T cells. DNA oligotyping of a lung carcinoma cell line established from this tumor revealed loss of one HLA haplotype corresponding with a translocation involving chromosome 6, as observed by COBRA-FISH. HLA class I-restricted tumor specific T cells could be isolated from PBMC. One further characterized cytotoxic CD8(+) T cell clone, that released TNF-alpha, IFN-gamma, and granzyme B upon co-incubation with the autologous tumor cells, was shown to be restricted by the remaining HLA-A11 allele, which was also shown to be expressed in the tumor tissue. Our data indicate that, despite HLA-haplotype loss a vigorous antitumor immune response mediated by CD8(+ )T-cells can be present in NSCLC offering possibilities for specific immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16924494     DOI: 10.1007/s00262-006-0214-y

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  7 in total

1.  Infiltration of CD8+ T cells into tumor cell clusters in triple-negative breast cancer.

Authors:  Xuefei Li; Tina Gruosso; Dongmei Zuo; Atilla Omeroglu; Sarkis Meterissian; Marie-Christine Guiot; Adam Salazar; Morag Park; Herbert Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-07       Impact factor: 11.205

2.  Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors.

Authors:  Hélène Salmon; Katarzyna Franciszkiewicz; Diane Damotte; Marie-Caroline Dieu-Nosjean; Pierre Validire; Alain Trautmann; Fathia Mami-Chouaib; Emmanuel Donnadieu
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

3.  DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis.

Authors:  Matjaz Humar; Martina Maurer; Marc Azemar; Bernd Groner
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-10       Impact factor: 4.553

Review 4.  Positive and negative influence of the matrix architecture on antitumor immune surveillance.

Authors:  Elisa Peranzoni; Ana Rivas-Caicedo; Houcine Bougherara; Hélène Salmon; Emmanuel Donnadieu
Journal:  Cell Mol Life Sci       Date:  2013-05-07       Impact factor: 9.261

Review 5.  The immunoregulatory mechanisms of carcinoma for its survival and development.

Authors:  Caigan Du; Yuzhuo Wang
Journal:  J Exp Clin Cancer Res       Date:  2011-01-21

6.  CD8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer.

Authors:  Jiewei Chen; Qingmei He; Jun Liu; Yongbo Xiao; Canhua Xiao; Keming Chen; Dan Xie; Xinke Zhang
Journal:  Cancer Manag Res       Date:  2018-09-13       Impact factor: 3.989

7.  Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.

Authors:  Jitske van den Bulk; Els M E Verdegaal; Dina Ruano; Marieke E Ijsselsteijn; Marten Visser; Ruud van der Breggen; Thomas Duhen; Manon van der Ploeg; Natasja L de Vries; Jan Oosting; Koen C M J Peeters; Andrew D Weinberg; Arantza Farina-Sarasqueta; Sjoerd H van der Burg; Noel F C C de Miranda
Journal:  Genome Med       Date:  2019-12-30       Impact factor: 11.117

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.